Business Context and Reporting Period
This Form 10-Q covers Spherix Incorporated (Note: Metadata listed "Dominari Holdings Inc." but the filing text identifies the registrant as Spherix Incorporated) for the quarterly period ended September 30, 2005. The company operates two principal segments: InfoSpherix, which provides contact center and reservation services primarily for government entities, and BioSpherix, which develops proprietary products including tagatose (a low-calorie sweetener) and related health applications.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2005 | Nine Months Ended Sept 30, 2005 |
|---|---|---|
| Revenue | $6,705,302 | $19,204,071 |
| Net Income (Loss) | $284,938 | $(560,458) |
| Operating Income (Loss) | $288,774 | $(568,502) |
| Net Cash Provided by Operating Activities | N/A (Quarterly) | $452,205 |
| Cash and Cash Equivalents | $3,894,696 | $3,894,696 |
| Working Capital | $5,036,234 | $5,036,234 |
| Bank Line of Credit Outstanding | $1,795,858 | $1,795,858 |
| Stockholders' Equity | $10,038,452 | $10,038,452 |
Material Changes vs. Prior Period
- Revenue: Decreased 5% ($386,000) for the quarter compared to 2004, driven by a new State of Maryland contract with lower rates and a temporary funding reduction on a federal contract. However, revenue increased 2% ($299,000) for the nine-month period due to new contracts (Georgia, FRTIB).
- Profitability: The company reported a net profit of $284,938 for the quarter, compared to $293,622 in the prior year. For the nine months, the company reported a net loss of $560,458, widening from a loss of $61,522 in the prior year.
- Segment Performance:
- InfoSpherix: Generated operating income of $479,000 for the quarter and $231,000 for the nine months. Revenue was impacted by hurricanes and rising gasoline prices reducing reservation volumes.
- BioSpherix: Reported an operating loss of $191,000 for the quarter and $800,000 for the nine months. Revenue dropped 98% quarter-over-year due to the sell-off of remaining FlyCracker inventory. Expenses increased significantly due to R&D activities.
- Cash Flow: Net cash provided by operating activities improved significantly to $452,205 for the nine months ended Sept 30, 2005, compared to a use of $130,658 in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
- Contract Disputes and Wins:
- NRRS Protest: The Government Accountability Office (GAO) sustained Spherix's protest against the USDA award of the National Recreation Reservation System (NRRS) contract to a competitor. The GAO recommended reopening the competition. Spherix expects reimbursement for significant legal costs.
- New Contracts: Awarded a five-year, ~$8 million contract with the Pennsylvania Department of Conservation and Natural Resources (revenue begins 2006). Selected as the offeror for the Michigan rebid (pending protest period).
- Liquidity and Capital Resources:
- SEDA Agreement: Entered a Standby Equity Distribution Agreement with Cornell Capital Partners to sell up to $4,000,000 of common stock over two years. This "equity line of credit" was established to maintain NASDAQ listing requirements (minimum $10M shareholders' equity) and fund operations.
- Line of Credit: Renewed a $2 million line of credit with Bank of America. $1.8 million was outstanding at period end, collateralized by a restricted CD.
- Corporate Structure: Shareholders approved the incorporation of InfoSpherix as a wholly-owned subsidiary, expected to be completed by year-end.
- Accounting Changes: The company must adopt FAS 123R (Share-Based Payment) in Q1 2006, which is expected to have an adverse impact on future statements of operations due to the fair-value measurement of stock options.
- Risks: BioSpherix royalty revenue is entirely dependent on the licensee (Arla) expanding manufacturing, which has not yet occurred. InfoSpherix revenue is seasonal and sensitive to government funding and external factors like fuel prices.
Investor Verification Checklist
- Verify the status of the NRRS contract protest and the timeline for the GAO's recommendation to be implemented by the USDA.
- Monitor the utilization of the Standby Equity Distribution Agreement (SEDA) and the resulting dilution to existing shareholders.
- Confirm the extension of the National Park Service (NPRS) contract beyond December 31, 2005, which accounted for 18% of nine-month revenue.
- Review the impact of the new FAS 123R accounting standard on Q1 2006 earnings when adopted.
- Assess the progress of BioSpherix clinical trials for Naturlose, particularly the follow-up to the University of Maryland study which showed mixed results.